Mainz enrols first subject in study to evaluate colorectal cancer test

Mainz enrols first subject in study to evaluate colorectal cancer test

Mainz Biomed has enrolled the first subject in its eAArly DETECT 2 feasibility study, aimed at evaluating colorectal cancer (CRC) test.The post Mainz enrols first subject in study to evaluate colorectal cancer test appeared first on Medical Device Network.

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - Mainz Biomed

2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report Top-Line Results in Fourth Quarter 2025 BERKELEY, US – MAINZ, Germany – March 27, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announce…